在当今这个信息爆炸的时代，如何精准把握市场动态，洞悉行业趋势，成为企业和投资者共同关注的焦点。为此，智研咨询分析团队倾力打造的《2025- 2031年中国百菌清行业市场行情监测及未来趋势研判报告》，旨在为各界精英提供最具研判性和实用性的行业分析。 本报告汇聚了智研咨询研究团队的集体智慧，结合国内外权威数据，深入剖析了百菌清行业的发展现状、竞争格局以及未来趋势。我们秉承专业、严谨的研 究态度，通过多维度、全方位的数据分析，力求为读者呈现一个清晰、立体的行业画卷。 在内容方面，报告不仅涵盖了行业的深度解读，还对百菌清产业进行了细致入微的探讨。无论是政策环境、市场需求，还是技术创新、资本运作，我们都进 行了详尽的阐述和独到的分析。此外，我们还特别关注了行业内的领军企业，深入剖析了它们的成功经验和市场策略。 百菌清，又名2,4,5,6-四氯-1,3-苯二腈，是一种有机化合物，化学式为C8Cl4N2，是一种广谱保护性杀菌剂。百菌清具有高效、低毒、广谱、低残留、药效期 长等优势，因此，相较传统保护性杀菌剂，百菌清需求量增长较快，特别是近两年来，因巴西大豆锈病暴发、全球病害抗性管理需求增长以及中国、印度、 东南亚等新兴市场 ...

Industry Overview - The pesticide industry in 2024 is under pressure but maintains stable development due to food security demands, showcasing trends in technological innovation and green transformation [2] - China, as the largest pesticide producer and exporter, is seeing an increase in technical capabilities and product variety, with top domestic companies experiencing revenue growth [2] - The upcoming "one certificate, one product" policy is expected to enhance industry standardization and sustainable development [2] Product Pricing and Trends - Current prices for key products are: - Abamectin: 515,000 CNY/ton - Methomyl: 720,000 CNY/ton - Bacillus thuringiensis: 27,000 CNY/ton - Prices are expected to rise, influenced by raw material costs and seasonal demand [3] Core Competencies - The company has strong resilience during industry downturns and has initiated cost-reduction strategies [3] - Production capacity includes: - Active ingredient capacity: 110,200 tons - Formulation capacity: 132,700 tons - The company holds 296 domestic pesticide registrations and 2,770 overseas registrations, indicating a robust product structure [3][5] Strategic Planning for 2025 - Focus on quality and cost efficiency for key products like Abamectin and Methomyl [6] - Enhance brand influence and market presence through new marketing strategies [6] - Accelerate international expansion, particularly in South America and Southeast Asia [6][8] - Drive research and development efficiency, emphasizing innovative product development [6] Financial Performance - In 2024, the company reported: - Revenue: 4.237 billion CNY, a 0.32% increase - Net profit: 81.36 million CNY, a 31.11% increase - Non-recurring net profit: 51.18 million CNY, a 12.52% increase [10] R&D and Innovation - The company is a pioneer in the industrial development of Abamectin and Methomyl, with a comprehensive product chain [5][13] - In 2024, the company established a synthetic biology laboratory to enhance product development capabilities [7][13] - New product projects are progressing, with 15 new patents granted in 2024 [8] Market Expansion and Risk Management - International revenue accounts for 33.89%, primarily from South America, Southeast Asia, and Africa [11] - The company employs financial derivatives to hedge against foreign exchange risks [11] - The impact of the US-China tariff conflict is minimal, with less than 2% of exports affected [16]

股票代码：002734 股票简称：利民股份 公告编号：2025-044 利民控股集团股份有限公司 关于召开 2024 年度股东大会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 利民控股集团股份有限公司（以下简称"公司"）于 2025 年 4 月 18 日在《中 国证券报》《证券时报》及巨潮资讯网(www.cninfo.com.cn)上刊登了《公司关于 召开 2024 年度股东大会的通知》（公告编号：2025-038），本次股东大会将采取 现场投票与网络投票相结合的方式召开，现再次将会议相关事项提示公告如下： 一、会议召开的基本情况 公司第六届董事会第四次会议决定于 2025 年 5 月 9 日召开 2024 年度股东大会， 具体内容如下： 1、会议召集人：公司董事会 2、本次股东大会的召开符合有关法律、行政法规、部门规章、规范性文件和 公司《章程》的相关规定。 3、会议召开时间： （1）现场会议召开时间：2025 年 5 月 9 日（星期五）14:30。 （2）网络投票时间：2025 年 5 月 9 日（星期五）。 其中，通过深圳证券交易所交易 ...

Investment Rating - The report indicates a positive outlook for the chemical industry, suggesting a new cycle may begin due to improved domestic supply and demand, increased global market share, and declining crude oil prices [3][4]. Core Viewpoints - The chemical industry is expected to enter a new cycle driven by domestic supply-demand improvements and global market share growth, despite potential short-term impacts from overseas demand [3][5]. - The report highlights that the supply side is gradually improving due to reduced fixed asset investment growth and government policies aimed at curbing excessive competition [5][10]. - On the demand side, domestic consumption is anticipated to recover steadily, supported by government initiatives to boost consumption and stabilize the economy [26][33]. - Cost factors are favorable, with significant declines in international crude oil and domestic coal prices, which will support the profitability of chemical products [42][49]. - The report recommends specific companies within various segments of the chemical industry, including refrigerants, amino acids, military and new materials, and fertilizers, indicating potential investment opportunities [5][57]. Summary by Sections Supply Side - The report notes that the chemical industry has faced profitability pressures since 2022, but the current production cycle is nearing its end, which may lead to gradual improvement in profitability as capacity is digested [11][12]. - China's global market share in chemical products has been steadily increasing, with 2023 figures showing a 43.1% share of global sales [25][20]. Demand Side - The report emphasizes that domestic demand is expected to recover, aided by government policies aimed at stimulating consumption and investment [26][33]. - The real estate sector shows signs of stabilization, which could further support demand for chemical products [33]. Cost Side - The report highlights a significant decline in crude oil prices, with Brent crude falling by 14.71% since the beginning of 2025, which is expected to positively impact the cost structure of the chemical industry [42][38]. - Domestic coal and natural gas prices have also shown a downward trend, enhancing the cost competitiveness of chemical products [49][47]. Valuation - The report indicates that the valuation of the basic chemical and petrochemical sectors is at historical lows, suggesting substantial room for recovery as market conditions improve [54][50].

Investment Rating - The report assigns a "Buy" rating for the company, marking it as the first recommendation [1][8]. Core Insights - The company achieved a total revenue of 4.237 billion yuan in 2024, with a slight year-on-year growth of 0.32%, while the net profit attributable to shareholders reached 81 million yuan, reflecting a significant increase of 31.11% [4]. - In Q1 2025, the company reported a total revenue of 1.211 billion yuan, showing a year-on-year growth of 22.28% and a quarter-on-quarter growth of 35.57%. The net profit attributable to shareholders surged to 108 million yuan, marking a year-on-year increase of 1373.23% and a quarter-on-quarter increase of 258.81% [4]. Summary by Sections Revenue and Market Performance - The company's overall revenue remained stable in 2024, with a notable divergence between domestic and international markets. The domestic market faced pressure due to intensified competition and fluctuations in agricultural product prices, leading to a 1.30% decline in revenue. In contrast, the international market contributed 1.436 billion yuan, accounting for 33.89% of total revenue, with a year-on-year increase of 3.64% [5]. Production Capacity and Cost Management - The company has a production capacity of 132,700 tons for formulations and 110,200 tons for active ingredients, with utilization rates of 85.98% and 78.86% respectively. Although the capacity remains industry-leading, the utilization rates are relatively low. The gross margins for key products, including agricultural fungicides, insecticides, and veterinary drugs, improved year-on-year, standing at 27.54%, 15.06%, and 21.46% respectively [5]. Research and Development - The company increased its R&D investment to 162 million yuan in 2024, with a 9.56% rise in the number of R&D personnel. The establishment of a synthetic biology laboratory and the development of new products, such as herbicide intermediates and fungicides, are expected to drive future growth [6][7]. Profit Forecast - The company is projected to achieve net profits of 260 million yuan, 374 million yuan, and 462 million yuan for the years 2025, 2026, and 2027 respectively, with corresponding price-to-earnings ratios of 21.3, 14.8, and 11.9 [8][10].

Investment Rating - The report maintains a recommendation for the chemical industry, indicating a positive outlook for the sector [6]. Core Viewpoints - The report highlights the significant price increases in active dyes (+10%) and PTA (+3.17%), suggesting potential investment opportunities in companies related to these products [4][20]. - It recommends focusing on companies like Huaitong Co., which is expected to benefit from the application of modified plastics in the robotics sector, and Runtong Co., which may gain from the rising prices of active dyes [5]. Industry Performance - In the first week of May, the chemical sector (Shenwan) experienced a decline of 0.50%, slightly underperforming the Shanghai A-share index, which fell by 0.49% [2][12]. - The dynamic PE ratio for the chemical sector stands at 24.05, which is lower than the average PE of 11.90 since 2015 [2][12]. Sub-industry Trends - Among the 15 sub-industries, five saw increases, with daily chemical products leading at +8.85%, while five sub-industries experienced declines, with synthetic leather dropping by -8.89% [3][15]. Price and Spread Trends - The report lists the top five products with the highest weekly price increases: active dyes (+10%), PTA (+3.17%), and butadiene (+2.86%) [4][20]. - The report also notes significant changes in price spreads, with the melamine spread increasing by +73.47% and the PTA spread by +39.52% [4][36]. Inventory Changes - Key products with notable inventory changes include potassium chloride (-17.88%) and epoxy propane (-8.96%), indicating shifts in supply dynamics [5][56].

Core Insights - The social security fund, managing 8 trillion yuan of national pension funds, is aggressively acquiring high-quality assets in the A-share market, which has a total market value of 100 trillion yuan [1][5] - A notable state-owned enterprise has seen its shares significantly increased by the social security fund, with a holding of 25.23 million shares and a remarkable growth of 4543% in its first-quarter report [3][4] Investment Trends - The first quarter is a critical period for institutional investors to position themselves for the year, and the investment moves of the social security fund often attract attention in the A-share market, potentially leading to unexpected returns [4] - In Q1 2023, the social security fund increased its holdings in a leading consumer software company by 2.8 million shares, resulting in a stock price surge of 460% [4] - In Q1 2024, the fund acquired 1.52 million shares of a leading CPO industry company, which subsequently saw its stock price double [4] Performance of Selected Companies - **Meige Intelligent**: Q1 expected growth of 611.31%, with the social security fund purchasing 22.59 million yuan worth of shares. The company specializes in wireless communication and has established partnerships with major enterprises [8] - **Haopeng Technology**: Q1 expected growth of 925.59%, with the fund buying 126 million yuan worth of shares. The company focuses on secondary battery technology and has a strong customer base [9] - **Chengdian International**: Q1 expected growth of 1327.65%, with the fund acquiring 22.44 million yuan worth of shares. The company operates in the public utility sector with a monopoly advantage [10] - **Limin Co., Ltd.**: Q1 expected growth of 1395.38%, with the fund purchasing 54.85 million yuan worth of shares. The company is a leading pesticide manufacturer with a strong market presence [11] - **Sichuan Shuangma**: Q1 expected growth of 1276.50%, with the fund buying 150 million yuan worth of shares. The company has successfully transitioned from traditional cement to private equity investment management [12] - **Leading ICT Infrastructure Company**: Q1 expected growth of 4726.52%, with the fund acquiring 25.24 million yuan worth of shares. The company is a key supplier for major internet firms and has seen foreign and insurance capital investments [13]

Group 1 - Over 3900 listed companies reported profits in Q1, indicating a strong start to the year, with major banks like ICBC, CCB, ABC, and BOC each exceeding 50 billion yuan in net profit [1] - BYD achieved revenue of 170.36 billion yuan in Q1, a year-on-year increase of 36.35%, with net profit reaching 9.155 billion yuan, up 100.38%, driven by strong growth in the new energy vehicle sector [1] - Sunshine Power reported revenue of 19.036 billion yuan, a 50.92% increase year-on-year, and net profit of 3.826 billion yuan, up 82.52%, with significant growth in inverter and energy storage segments [2] Group 2 - Cambrian Technology reported revenue of 1.111 billion yuan, a staggering increase of 4230.22% year-on-year, and net profit of 355 million yuan, marking a turnaround from losses [2] - Limin Co. turned a profit with net profit rising from a loss of 8.4917 million yuan to 108 million yuan, benefiting from price increases and higher sales in the domestic pesticide sector [2] - Companies like Jintan and Haopeng Technology are optimistic about 2025, focusing on high-margin markets and value customers, with expectations of steady profit growth through cost reduction and technological upgrades [3][4] Group 3 - Jintan plans to increase its old renovation business from 15% to 50% in 2024, while expanding overseas operations in regions like Southeast Asia and the Middle East [3] - GCL-Poly Energy aims to increase the share of energy service revenue to over 50% in the next five years, focusing on building a collaborative ecosystem around energy services [4] - Companies are generally confident about maintaining over 20% growth in revenue and profit by 2025, despite facing external uncertainties [3]

股票代码：002734 股票简称：利民股份 公告编号：2025-043 利民控股集团股份有限公司 关于质量回报双提升行动方案的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 利民控股集团股份有限公司（以下简称"公司"）为践行中共中央政治局会议 提出的"要活跃资本市场、提振投资者信心"及国务院常务会议提出的"要大力提 升上市公司质量和投资价值，采取更加有力有效措施，着力稳市场、稳信心"的指 导思想，坚持"以投资者为本"的发展理念，维护全体股东利益，增强投资者信心， 促进公司长远健康可持续发展，公司制定了"质量回报双提升"行动方案（以下简 称"《行动方案》"），具体内容详见公司于 2024 年 6 月 19 日在巨潮资讯网上披 露的《关于推动落实质量回报双提升行动方案的公告》（公告编号：2024-049）。 自制定并披露《行动方案》以来，公司多措并举积极落实方案内容，现将方案进展 情况公告如下： 一、进一步完善治理结构，规范公司治理 公司严格按照《中华人民共和国公司法》《中华人民共和国证券法》等法律法 规和中国证监会与深圳证券交易所的有关规定，持续完善以 ...

Core Viewpoint - The agricultural chemical industry is experiencing a recovery in the first quarter of 2024, with most companies reporting improved performance after a period of destocking in 2023 [1][5][6]. Group 1: Company Performance - As of April 28, 29 agricultural chemical companies have disclosed their Q1 reports, with 27 companies reporting profits and 16 showing year-on-year profit growth [1]. - Companies such as Lianhua Technology, Hunan Haili, and Lier Chemical reported net profit increases exceeding 100% year-on-year [2][3]. - Lianhua Technology's Q1 net profit grew over tenfold to 4971.56 million yuan, with a revenue of 15.1 billion yuan, marking a 3.02% increase [2]. - Hunan Haili achieved a revenue of 4.31 billion yuan, up 25.44%, and a net profit of 5661.02 million yuan, up 483.78% [3]. - Lier Chemical reported total revenue of 20.86 billion yuan, a 49.99% increase, and a net profit of 1.53 billion yuan, up 219.9% [3]. - Companies like Xianda Co. and Limin Co. turned losses into profits in Q1 due to increased sales and prices [4]. Group 2: Market Trends - The agricultural chemical market is entering its traditional peak season, with significant destocking observed since the beginning of the year [5][6]. - The market is showing signs of recovery, with an increase in terminal demand and replenishment in both domestic and foreign markets [6]. - The raw material price index for agricultural chemicals rose to 73.11 points, reflecting a 0.29% increase from the previous month [6]. - Industry experts express optimism for 2025, anticipating a stable recovery in the agricultural chemical sector [7].